| Hazard Information | Back Directory | [Uses]
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD)[1][2][3][4]. | [in vivo]
Itepekimab ameliorates type 1 and type 2 lung inflammation and prevents characteristic lung remodeling in mice. Itepekimab prevents IL-33/ST2/IL-1RAcP complex formation and reconstitutes ciliated cells in a mouse model of persistent airway inflammation[4].
| [References]
[1] Wechsler ME, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-1668. DOI:10.1056/NEJMoa2024257
[2] Rabe KF, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021 Nov;9(11):1288-1298. DOI:10.1016/S2213-2600(21)00167-3
[3] Kosloski MP, et al. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials. Clin Transl Sci. 2022 Feb;15(2):384-395. DOI:10.1111/cts.13157 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|